Danaher Corporation Q4 2025 Earnings Call Highlights
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21h ago
0mins
Source: seekingalpha
- Strong Performance: Danaher reported $24.6 billion in sales for Q4 2025, with core revenue growth of 2% and adjusted diluted EPS of $7.80, reflecting robust performance in bioprocessing and diagnostics.
- Innovation-Driven Growth: Cytiva launched over 20 new products, positioning the bioprocessing segment for anticipated high single-digit core revenue growth in 2026, underscoring the company's competitive edge in the biotech market.
- Strong Cash Flow: The company generated $5.3 billion in free cash flow in Q4, achieving a free cash flow to net income conversion ratio of approximately 145%, providing solid support for future investments and shareholder returns.
- Optimistic Outlook: Management anticipates core revenue growth of 3% to 6% for 2026 and has initiated adjusted diluted EPS guidance in the range of $8.35 to $8.50, reflecting confidence in market recovery.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DHR is 261.57 USD with a low forecast of 235.00 USD and a high forecast of 310.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
15 Buy
2 Hold
0 Sell
Strong Buy
Current: 224.540
Low
235.00
Averages
261.57
High
310.00
Current: 224.540
Low
235.00
Averages
261.57
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Danaher Set to Announce Q4 Earnings on January 28
- Earnings Announcement: Danaher is scheduled to release its Q4 earnings on January 28 before market open, with a consensus EPS estimate of $2.19, reflecting a 2.3% year-over-year increase, which could influence investor confidence in the company's future performance.
- Revenue Expectations: The anticipated revenue for Q4 is $6.81 billion, representing a 4.8% year-over-year growth, and achieving this target would further solidify Danaher's market position in the biotech sector and enhance its financial stability.
- Performance Beat Record: Over the past two years, Danaher has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, which raises market expectations for its upcoming earnings report.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, while revenue estimates have experienced two upward and two downward revisions, indicating analyst divergence and market uncertainty regarding the company's future performance.
Continue Reading
Mixed Close for US Stocks as Chipmakers Rally
- Chipmaker Strength: ASML reported record Q4 bookings of €13.2 billion, significantly exceeding the consensus of €6.85 billion, which boosted chipmakers and AI infrastructure stocks, enhancing market confidence in AI spending sustainability.
- Fed Policy Unchanged: The FOMC maintained the interest rate at 3.50%-3.75% as expected, with Chair Powell indicating strong economic performance without signaling imminent rate cuts, keeping market focus on future policy directions.
- Dollar and Gold Fluctuations: The dollar index rebounded after hitting a nearly four-year low, while President Trump's comments on dollar weakness pushed gold prices up over 3% to a new all-time high, reflecting increased demand for safe-haven assets.
- Economic Data Expectations: Initial jobless claims are expected to rise by 5,000 to 205,000 this week, and Q3 nonfarm productivity is anticipated to remain at 4.9%, indicating ongoing economic growth and potential market volatility.
Continue Reading